Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 25, 2015 (12 years ago)

GLIPIZIDE and METFORMIN HYDROCHLORIDE Tablets (Glipizide and Metformin HCL)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Impurities/Degradation Specifications: Out of specification for unknown impurity.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

GLIPIZIDE and METFORMIN HYDROCHLORIDE Tablets, USP, 2.5 mg/500 mg, 100 ct Bottles, Rx Only. Manufactured for: Heritage Pharmaceuticals Inc. Eatontown, NJ 07724, NDC: 23155-116-01.

Affected NDC 23155-0116-01

Compare with the code on your package — it is the most precise check available.

Drug: Metformin Category: Diabetes Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Glipizide and Metformin HCl
NDC 23155-0116
GLIPIZIDE 2.5 mg/1; METFORMIN HYDROCHLORIDE 500 mg/1 Tablet, Film Coated
Oral
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. Rx
Recalling firm
Heritage Pharmaceuticals, Inc.
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0436-2015 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Metformin recalls

See all
Class II · Moderate risk

Synjardy XR Tablets

CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.

Ongoing cGMP deviation Boehringer Ingelheim Pharmaceuticals, Inc. D-0657-2026

Other recalls by Heritage Pharmaceuticals, Inc.

All 2015 recalls
Class II · Moderate risk

Desipramine Hydrochloride Tablets

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Ongoing Nitrosamine impurity Heritage Pharmaceuticals Inc NDC 23155-583-25 D-0112-2026
Class II · Moderate risk

Desipramine Hydrochloride Tablets

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Ongoing Nitrosamine impurity Heritage Pharmaceuticals Inc NDC 23155-582-01 D-0111-2026
Class II · Moderate risk

Desipramine Hydrochloride Tablets

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Ongoing Nitrosamine impurity Heritage Pharmaceuticals Inc NDC 23155-581-01 D-0110-2026